| Table 2: Therapeutic effects of Graptopetalum paraguayense (GP) on DMN-induced liver fibrosis in rats via biochemical analysis (1). |
| | Categorical variable |
| | Numeric variable | | DMN | DMN + GP | | Control (n)a | 1st to 2nd wk (n)b | 3rd to 4th wk (n)b | 5th to 6th wk (n)b | 2nd wk (n)c | 3rd to 4th wk (n)c | 5th to 6th wk (n)c |
| | Albumin (g/dL) | 4.6 ± 0.3 (23) | 3.9 ± 0.7 (07) | 3.5 ± 0.6 (11) | 3.2 ± 0.1 (07) | 3.7 ± 0.5 (06) | 4.0 ± 0.7 (12) | 4.3 ± 0.6 (14) | | GPT (U/L) | 58.8 ± 19.6 (23) | 459.5 ± 78.5 (08) | 566.6 ± 313.5 (11) | 763.6 ± 405.2 (07) | 235.0 ± 128.6 (06) | 207.0 ± 111.7 (12) | 262.5 ± 386.2 (14) | | GOT (U/L) | 101.9 ± 30.4 (23) | 661.5 ± 134.4 (08) | 1006.1 ± 749.6 (11) | 1572.9 ± 965.3 (07) | 271.3 ± 106.0 (06) | 190.4 ± 114.5 (12) | 218.0 ± 259.6 (14) | | Bilirubin (mg/dL) | 0.11 ± 0.04 (24) | 0.72 ± 0.53 (08) | 1.00 ± 0.74 (11) | 1.13 ± 1.00 (07) | 0.25 ± 0.14 (06) | 0.25 ± 0.20 (12) | 0.3 ± 0.32 (14) | | AKP (KA) | 45.9 ± 7.5 (12) | 600.8 ± 93.0 (04) | 668.3 ± 222.0 (03) | 468 ± 12.7 (02) | 298.2 ± 65.8 (04) | 353.3 ± 62.3 (08) | 374.0 ± 88.3 (11) | | LDH (IU/L) | 280.5 ± 49.0 (11) | 414.8 ± 102.7 (04) | 562.0 ± 120.8 (03) | 853.5 ± 91.2 (02) | 352.0 ± 21.9 (04) | 378.6 ± 36.1 (08) | 329.5 ± 67.6 (11) | | Globulin (g/dL) | 7.0 ± 0.4 (11) | 6.65 ± 0.1 (02) | 5.0 ± 0.84 (04) | 3.6 ± 03 (02) | 5.9 ± 0.6 (04) | 5.7 ± 0.5 (08) | 5.9 ± 1.0 (11) | | Triglyceride (mg/dL) | 148.0 ± 33.7 (12) | 151.3 ± 107.3 (04) | 180.9 ± 144.4 (07) | 102.8 ± 35.1 (05) | 73.0 ± 26.9 (02) | 96.5 ± 29.9 (08) | 98.3 ± 32.2 (11) | | AFP (ng/dL) | 0.26 ± 0.06 (10) | 0.40 ± 0.19 (04) | 0.38 ± 0.05 (04) | 0.35 ± 0.07 (02) | 0.20 ± 0.00 (02) | 0.28 ± 0.13 (08) | 0.26 ± 0.08 (10) | | CHOL (mg/dL) | 83.2 ± 0.14.1 (12) | 76.5 ± 7.9 (04) | 69.5 ± 12.8 (06) | 66.6 ± 17.5 (05) | 60.0 ± 5.0 (04) | 65.9 ± 15.5 (08) | 70.8 ± 18.6 (11) | | BUN (mg/dL) | 27.2 ± 6.0 (12) | 32.5 ± 3.9 (04) | 36.25 ± 2.2 (04) | 30.5 ± 4.9 (02) | 18.8 ± 3.9 (04) | 20.9 ± 2.2 (08) | 30.6 ± 23.0 (11) | | ACP (mg/dL) | 2.4 ± 0.6 (12) | 1.9 ± 0.6 (04) | 6.2 ± 1.1 (04) | 8.2 ± 0.6 (02) | 3.8 ± 0.6 (04) | 5.0 ± 1.5 (08) | 3.7 ± 1.1 (11) | | PT (sec) | 13.1 ± 1.1 (22) | 18.5 ± 4.0 (08) | 19.7 ± 4.3 (09) | 21.5 ± 4.6 (06) | 16.1 ± 2.6 (06) | 17.2 ± 5.4 (10) | 16.3 ± 2.9 (13) | | PLT (103/mL) | 871.5 ± 191.8 (24) | 406.6 ± 71.7 (07) | 300.2 ± 164.7 (11) | 228.6 ± 302.4 (07) | 535.3 ± 137.9 (06) | 548.9 ± 259.1 (12) | 704.5 ± 301.1 (14) |
|
|
a: Mean ± SD of value from 1st to 6th week in control groups.
b: Mean ± SD of value from 1st to 2nd, 3rd to 4th or 5th to 6th week in DMN treatment groups.
c: Mean ± SD of value from 2nd, 3rd to 4th or 5th to 6th week in DMN+GP treatment groups.
n: number of rats.
|